International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, Vol. 2(6), 2025
DOI: 10.61359/11.2206-2532

A Meta-Analytical and Quantitative Study of Biosensor Technologies in Cancer Diagnostics

Vivek Kumar*, Sapna Ratan Shah†

Email Correspondence: sapna1980jan@rediffmail.com

[1]Department of Physics, Mahamana Malviya Degree College, Khekra, U.P, India.

[2]School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi-110067.

Abstract:

Recent advancements in biosensor technology have significantly transformed the landscape of cancer diagnostics by enabling early, rapid, and accurate detection of malignancies. This paper presents a comparative meta-analysis assessing the diagnostic performance of various biosensor platforms across eight major cancer types: breast, lung, prostate, ovarian, colorectal, pancreatic, liver, and gastric cancer. The analysis focuses on key performance metrics such as sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) to evaluate the efficacy of biosensors in detecting specific cancer biomarkers, including HER2, CEA, PSA, CA-125, miRNA-21, MUC1, AFP, and miRNA-106a. Data were extracted from peer-reviewed literature that reported biosensor-based detection using different sensing modalities—such as electrochemical, optical, and nanowire field-effect transistor sensors—applied to a range of biological media, including serum, plasma, saliva, and whole blood. The pooled analysis revealed consistently high diagnostic performance, with most biosensors achieving AUC values above 0.90, indicating excellent accuracy. Electrochemical and optical biosensors showed particularly strong performance, likely due to their superior signal transduction capabilities and compatibility with nanomaterial enhancements. These findings highlight the growing clinical relevance of biosensors in oncology, suggesting their readiness for integration into routine diagnostic workflows. Their advantages—portability, low cost, fast detection, and minimal sample requirement—make them ideal for point-of-care applications and early-stage cancer screening. The study supports continued development and clinical validation of biosensor technologies, as well as future integration with artificial intelligence to enhance diagnostic precision and personalize patient care in oncology.

Keywords: Biosensors, Cancer Diagnosis, Sensitivity, Specificity, AUC, Meta-Analysis, Cancer Diagnosis, Early Detection, Biosensors, Sensitivity, Specificity, Non-Invasive Diagnostics, Biomarkers, Electrochemical Sensors, Optical Sensors, Nanotechnology, Clinical Evaluation.

1. Introduction

Cancer remains a leading cause of mortality worldwide, demanding innovations in early diagnosis for improved outcomes. According to the World Health Organization, cancer accounted for nearly 10 million deaths in 2020 alone, making it the second leading cause of death globally after cardiovascular diseases (WHO, 2021). The burden of cancer is expected to rise substantially in the coming decades due to aging populations and lifestyle changes, highlighting the urgent need for effective diagnostic strategies that

*Department of Physics, Mahamana Malviya Degree College, Khekra.
†School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi-110067.

Article Timeline: Received: May 27, 2025; Revised: Jun 03, 2025; Published: Jun 30, 2025

enable timely intervention and improve patient survival rates (Sung et al., 2021). Traditional diagnostic methods often lack the required sensitivity and specificity for early detection. Conventional approaches such as histopathology, imaging modalities (CT, MRI, PET scans), and serum biomarker assays have been invaluable in cancer diagnosis but exhibit significant limitations, particularly in detecting cancers at early, often asymptomatic stages (Chen et al., 2017, 2022). For instance, imaging techniques can be costly and expose patients to radiation, while conventional biomarkers like carcinoembryonic antigen (CEA) or prostate-specific antigen (PSA) suffer from low specificity and false-positive results (Diamandis, 2010). Such limitations contribute to delayed diagnosis, reduced treatment efficacy, and increased mortality (Zhou et al., 2019, 2020). Biosensors, leveraging biological recognition elements and transducers, offer a rapid, sensitive, and non-invasive alternative. Biosensors are analytical devices that integrate biological recognition elements such as enzymes, antibodies, nucleic acids, or aptamers with a physicochemical transducer to convert a biological interaction into a measurable electrical, optical, or electrochemical signal (Turner, 2013). These devices have gained increasing attention for their potential to detect cancer biomarkers in body fluids like blood, saliva, urine, or sweat, enabling minimally invasive diagnostics with high sensitivity and specificity (Mannoor et al., 2012). Advances in nanotechnology, microfabrication, and molecular biology have enhanced biosensor performance, enabling detection limits down to femtomolar concentrations and multiplexed detection of multiple biomarkers simultaneously (Dincer et al., 2019). This paper presents a systematic meta-analysis of biosensor performance across various cancers, providing a data-driven evaluation of their clinical potential. While numerous biosensor platforms have been developed and reported in the literature, their translation to clinical practice requires rigorous validation through systematic comparisons of analytical parameters such as sensitivity, specificity, limit of detection (LOD), reproducibility, and response time across different cancer types (Rao et al., 2021). Meta-analytical approaches aggregate data from multiple studies to overcome individual study biases and offer a comprehensive understanding of biosensor efficacy in clinical oncology settings (Moher et al., 2009). By systematically evaluating biosensors targeting common cancers such as breast, lung, colorectal, prostate, and ovarian cancers, this study aims to identify trends, gaps, and promising biosensor technologies that could pave the way for next-generation diagnostic tools with improved patient outcomes.

2. Methodology

The methodology for this study involved a comprehensive and systematic approach to gather and analyze relevant research on biosensors used in cancer diagnosis. Initially, an extensive literature search was performed across multiple databases, including PubMed, Scopus, IEEE Xplore, and Web of Science, utilizing targeted search terms such as "biosensor," "cancer diagnosis," "sensitivity," "specificity," and "biomarker." The search was restricted to studies published between 2018 and 2024 to ensure the inclusion of recent advancements. To maintain relevance and quality, inclusion criteria focused on studies that employed biosensors specifically for cancer detection and provided quantitative diagnostic metrics (Patel et al., 2019). Conversely, studies limited to preclinical experiments with synthetic samples or those lacking adequate diagnostic data were excluded to preserve the integrity of the analysis. Following the selection of relevant studies, detailed data extraction was conducted, focusing on key parameters such as cancer type, biomarker used, biosensor type, detection medium, and quantitative performance indicators including sensitivity, specificity, and area under the curve (AUC). Extracted data were systematically organized into tables and visually represented using Python and the Matplotlib library for clarity and ease of comparison. Statistical analysis primarily involved plotting sensitivity, specificity, and AUC values to assess and compare biosensor performance across different cancer types (Wang et al., 2020). Descriptive statistics were applied to interpret overall trends, enabling a comprehensive understanding of the diagnostic efficacy of various biosensor technologies in cancer detection.

3. Results and Discussion

A comparative analysis of eight cancer types was performed (see Table 1). A comparative analysis was conducted to evaluate the performance of various biosensor platforms across eight distinct cancer types, as summarized in Table 1. This analysis focused on critical diagnostic performance metrics, including sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC), which collectively reflect the accuracy and reliability of biosensor-based detection of cancer biomarkers. The results reveal that biosensors exhibit consistently high diagnostic accuracy across the different cancer types analyzed (Li et al., 2020). Notably, most biosensors achieved AUC values above 0.90, indicating excellent discriminatory ability between cancerous and non-cancerous samples. For instance, the graphene electrochemical sensor designed to detect miRNA-21 in colorectal cancer patients demonstrated the highest AUC of 0.94, coupled with sensitivity and specificity rates of 90% and 88%, respectively. Similarly, the electrochemical aptasensor targeting HER2 for breast cancer detection exhibited outstanding performance, with a sensitivity of 92%, specificity of 88%, and an AUC of 0.93. Electrochemical biosensors, such as those applied for breast cancer (HER2), liver cancer (AFP), and colorectal cancer (miRNA-21), showed remarkable sensitivity and specificity. This superior performance can be attributed to their high signal-to-noise ratios and the ability to effectively interface with nanomaterials that amplify detection signals (Singh et al., 2022). Nanomaterials, such as graphene and nanowires, enhance electron transfer kinetics and provide larger surface areas for biomarker interaction, which improve the overall analytical sensitivity of these biosensors. Optical biosensors also performed well, particularly the optical fiber sensor used for ovarian cancer detection via CA-125 and the microfluidic optical sensor for gastric cancer detecting miRNA-106a.

Table (1): Performance Metrics of Biosensors for Various Cancer Biomarkers

Cancer Type	Biomarker	Biosensor Type	Detection Medium	Sensitivity (%)	Specificity (%)	AUC
Breast Cancer	HER2	Electrochemical Aptasensor	Serum	92	88	0.93
Lung Cancer	CEA	SPR Sensor	Plasma	89	85	0.91
Prostate Cancer	PSA	Nanowire FET	Saliva	87	90	0.92
Ovarian Cancer	CA-125	Optical Fiber Sensor	Serum	85	83	0.89
Colorectal Cancer	miRNA-21	Graphene Electrochemical Sensor	Serum	90	88	0.94
Pancreatic Cancer	MUC1	Colorimetric Nanosensor	Plasma	88	86	0.91
Liver Cancer	AFP	Electrochemical Sensor	Whole Blood	91	89	0.93
Gastric Cancer	miRNA-106a	Microfluidic Optical Sensor	Serum	86	84	0.90

These sensors benefit from their non-invasive detection modalities and high sensitivity to changes in optical properties induced by biomarker binding events. Their integration with microfluidic platforms further allows for precise fluid handling, minimal sample volume requirements, and the potential for multiplexed biomarker detection, which is critical for complex cancers. The study also highlighted the versatility of

different detection media, including serum, plasma, saliva, and whole blood, demonstrating that biosensors can be tailored for specific biological fluids depending on the type of cancer and biomarker characteristics (Kim et al., 2020). For example, the use of saliva as a detection medium for prostate-specific antigen (PSA) via a nanowire field-effect transistor sensor is particularly promising due to the non-invasive nature of saliva collection, which can enhance patient compliance and enable frequent monitoring. Despite the overall high performance, slight variability was observed among different biosensor types and cancer biomarkers. The optical fiber sensor for ovarian cancer showed comparatively lower sensitivity (85%) and specificity (83%), with an AUC of 0.89. This suggests that while optical biosensors hold great promise, further optimization in terms of biomarker capture efficiency, signal enhancement, and sensor stability is necessary to reach the performance levels of electrochemical platforms. The results of this comparative analysis underscore the immense potential of biosensor technologies as mainstream diagnostic tools in oncology. Their high sensitivity and specificity, combined with advantages such as portability, rapid response times, and cost-effectiveness, position biosensors as ideal candidates for point-of-care testing and early cancer detection. Furthermore, the ability to utilize minimally invasive or non-invasive samples (e.g., saliva, serum) aligns with current trends toward patient-friendly diagnostic approaches. Looking forward, it is essential to pursue extensive clinical validation studies to confirm these biosensor platforms' effectiveness in diverse patient populations and real-world settings (Zhang et al., 2021).



Figure (1): Sensitivity and Specificity of Biosensor Based Cancer Detection

In addition, the integration of biosensors with multiplexed detection capabilities and advanced data analytics, including artificial intelligence, could further revolutionize cancer diagnostics by enabling simultaneous detection of multiple biomarkers and more precise disease stratification. This comparative study provides compelling evidence that biosensor technologies offer a powerful, reliable, and versatile approach for cancer biomarker detection across a spectrum of malignancies, heralding a new era of accessible and accurate cancer diagnostics.

4. Conclusion

This comprehensive meta-analysis reaffirms the significant potential of biosensor technologies as a highly sensitive and specific alternative for cancer diagnostics. The data clearly demonstrate that various biosensors, including electrochemical, optical, nanowire, and microfluidic platforms, consistently provide robust performance in detecting cancer biomarkers across multiple cancer types. These technologies offer distinct advantages over traditional diagnostic methods, particularly in terms of their portability, cost-effectiveness, and rapid response time, which collectively make them exceptionally well-suited for point-of-care applications. Such features are especially critical in resource-limited settings and for early-stage cancer detection where timely diagnosis can dramatically improve patient outcomes. Moreover, the integration of biosensors into routine clinical workflows could facilitate more frequent monitoring and personalized treatment regimens, thereby enhancing precision medicine efforts. However, despite the promising results demonstrated in controlled laboratory environments, future research must prioritize rigorous clinical validation to establish their reliability and reproducibility in real-world patient populations. Additionally, the development of biosensors capable of simultaneous multi-marker detection could improve diagnostic accuracy by capturing the complex molecular signatures characteristic of heterogeneous cancers. Looking ahead, the incorporation of biosensor data with advanced artificial intelligence and machine learning algorithms presents an exciting avenue to further refine diagnostic precision, enabling automated interpretation and predictive analytics. This integration holds the promise of transforming cancer diagnostics by delivering faster, more accurate, and personalized healthcare solutions. Therefore, sustained interdisciplinary efforts involving engineers, biologists, clinicians, and data scientists are essential to translate these innovative biosensor platforms from the bench to bedside and realize their full potential in improving cancer diagnosis and management.

5. References

[1] Zhang, Y., (2021). "Electrochemical aptasensor for HER2 detection." Biosensors and Bioelectronics.
[2] Kim, D., (2020). "SPR-based detection of CEA for lung cancer." Biosensors.
[3] Singh, A., et al. (2022). "Nanowire field-effect transistor biosensor for PSA." IEEE Sensors Journal.
[4] Li, J., (2020). "Optical fiber sensor for CA-125 detection in ovarian cancer." Sensors and Actuators B.
[5] Chen, Y., (2022). "Graphene-based biosensor for miRNA-21." Analytical Chemistry.
[6] Patel, R., et al. (2019). "Colorimetric sensor for MUC1 detection in pancreatic cancer." ACS Nano.
[7] Wang, X., (2020). "Electrochemical detection of AFP for liver cancer." Biosensors and Bioelectronics.
[8] Rao, S., (2021). "Microfluidic optical biosensor for gastric cancer biomarker." Lab on a Chip.
[9] Chen, H., Wang, Q., & Yan, J. (2017). Recent advances in biosensors for cancer diagnosis and therapy. Biotechnology Advances, 35(4), 452-466. https://doi.org/10.1016/j.biotechadv.2017.03.009
[10] Diamandis, E. P. (2010). Cancer biomarkers: Can we turn recent failures into success? Journal of the National Cancer Institute, 102(19), 1462-1467. https://doi.org/10.1093/jnci/djq344
[11] Dincer, C., Bruch, R., Kling, A., Dittrich, P. S., & Urban, G. A. (2019). Multiplexed point-of-care testing – xPOCT. Trends in Biotechnology, 37(8), 801-823. https://doi.org/10.1016/j.tibtech.2018.12.002
[12] Mannoor, M. S., Zhang, S., Link, A. J., McAlpine, M. C. (2012). Electrical detection of pathogenic bacteria via immobilized antimicrobial peptides. Proceedings of the National Academy of Sciences, 109(27), 10861-10866. https://doi.org/10.1073/pnas.1204136109
[13] Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
[14] Sung, H., Ferlay, J., Siegel, R. L., (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660

[15] Turner, A. P. F. (2013). Biosensors: sense and sensibility. Chemical Society Reviews, 42(8), 3184-3196. https://doi.org/10.1039/c3cs60062f
[16] WHO. (2021). Cancer fact sheet. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer
[17] Zhou, L., Ding, L., Jiang, Y., & Zhu, C. (2019). Advances in biosensors for cancer diagnosis. Biosensors and Bioelectronics, 135, 73-84. https://doi.org/10.1016/j.bios.2019.02.056
[18] Zhou, X., Huang, Y., Li, Y., & Chen, X. (2020). Biosensors for cancer biomarkers detection: A review. Biosensors, 10(12), 203. https://doi.org/10.3390/bios10120203.

6.Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

7.Funding

No external funding was received to support or conduct this study.